Trials / Completed
CompletedNCT00432770
Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers
A Phase 1, Single-Site, Double-Blind,Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (planned)
- Sponsor
- Archemix Corp. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity.
Detailed description
The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARC1779 |
Timeline
- Start date
- 2006-12-01
- Completion
- 2007-03-01
- First posted
- 2007-02-08
- Last updated
- 2007-04-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00432770. Inclusion in this directory is not an endorsement.